Peptide	B:C0030956
-	O
based	O
vaccination	O
against	O
Osteopontin	O
integrin	O
binding	O
sites	I:C0005456
does	O
not	O
improve	O
cardio-	O
metabolic	I:C0012634
disease	I:C0012634
in	O
mice	O
.	O

Peptide	O
-	O
based	O
vaccination	B:C0042196
against	O
Osteopontin	O
integrin	O
binding	O
sites	I:C0005456
does	O
not	O
improve	O
cardio-	O
metabolic	I:C0012634
disease	I:C0012634
in	O
mice	O
.	O

Peptide	O
-	O
based	O
vaccination	O
against	O
Osteopontin	B:C0069676
integrin	O
binding	O
sites	I:C0005456
does	O
not	O
improve	O
cardio-	O
metabolic	I:C0012634
disease	I:C0012634
in	O
mice	O
.	O

Peptide	O
-	O
based	O
vaccination	O
against	O
Osteopontin	O
integrin	B:C0021701
binding	O
sites	I:C0005456
does	O
not	O
improve	O
cardio-	O
metabolic	I:C0012634
disease	I:C0012634
in	O
mice	O
.	O

Peptide	O
-	O
based	O
vaccination	O
against	O
Osteopontin	O
integrin	O
binding	B:C0005456
sites	I:C0005456
does	O
not	O
improve	O
cardio-	O
metabolic	I:C0012634
disease	I:C0012634
in	O
mice	O
.	O

Peptide	O
-	O
based	O
vaccination	O
against	O
Osteopontin	O
integrin	O
binding	O
sites	I:C0005456
does	O
not	O
improve	O
cardio-	B:C0012634
metabolic	I:C0012634
disease	I:C0012634
in	O
mice	O
.	O

Peptide	O
-	O
based	O
vaccination	O
against	O
Osteopontin	O
integrin	O
binding	O
sites	I:C0005456
does	O
not	O
improve	O
cardio-	O
metabolic	I:C0012634
disease	I:C0012634
in	O
mice	B:C0026809
.	O

Obesity	B:C0028754
causes	O
insulin	O
resistance	I:C0021655
via	O
a	O
chronic	O
low	O
-	O
grade	O
inflammation	O
.	O

Obesity	O
causes	O
insulin	B:C0021655
resistance	I:C0021655
via	O
a	O
chronic	O
low	O
-	O
grade	O
inflammation	O
.	O

Obesity	O
causes	O
insulin	O
resistance	I:C0021655
via	O
a	O
chronic	O
low	O
-	O
grade	O
inflammation	B:C0021368
.	O

This	O
inflammation	B:C0021368
is	O
characterized	O
by	O
elevated	O
pro-inflammatory	O
markers	O
and	O
macrophage	O
accumulation	O
in	O
the	O
adipose	O
tissue	I:C0001527
(	O
adipose	O
tissue	I:C0001527
)	O
.	O

This	O
inflammation	O
is	O
characterized	O
by	O
elevated	O
pro-inflammatory	B:C0243095
markers	O
and	O
macrophage	O
accumulation	O
in	O
the	O
adipose	O
tissue	I:C0001527
(	O
adipose	O
tissue	I:C0001527
)	O
.	O

This	O
inflammation	O
is	O
characterized	O
by	O
elevated	O
pro-inflammatory	O
markers	B:C0005516
and	O
macrophage	O
accumulation	O
in	O
the	O
adipose	O
tissue	I:C0001527
(	O
adipose	O
tissue	I:C0001527
)	O
.	O

This	O
inflammation	O
is	O
characterized	O
by	O
elevated	O
pro-inflammatory	O
markers	O
and	O
macrophage	B:C0024432
accumulation	O
in	O
the	O
adipose	O
tissue	I:C0001527
(	O
adipose	O
tissue	I:C0001527
)	O
.	O

This	O
inflammation	O
is	O
characterized	O
by	O
elevated	O
pro-inflammatory	O
markers	O
and	O
macrophage	O
accumulation	B:C4055506
in	O
the	O
adipose	O
tissue	I:C0001527
(	O
adipose	O
tissue	I:C0001527
)	O
.	O

This	O
inflammation	O
is	O
characterized	O
by	O
elevated	O
pro-inflammatory	O
markers	O
and	O
macrophage	O
accumulation	O
in	O
the	O
adipose	B:C0001527
tissue	I:C0001527
(	O
adipose	O
tissue	I:C0001527
)	O
.	O

This	O
inflammation	O
is	O
characterized	O
by	O
elevated	O
pro-inflammatory	O
markers	O
and	O
macrophage	O
accumulation	O
in	O
the	O
adipose	O
tissue	I:C0001527
(	O
adipose	B:C0001527
tissue	I:C0001527
)	O
.	O

AT	B:C0030326
inflammation	I:C0030326
is	O
a	O
key	O
factor	O
causing	O
insulin	O
resistance	I:C0021655
and	O
thus	O
type	O
2	I:C0011860
diabetes	I:C0011860
,	O
both	O
linked	O
to	O
atherosclerotic	O
cardiovascular	I:C0004153
disease	I:C0004153
.	O

AT	O
inflammation	I:C0030326
is	O
a	O
key	O
factor	O
causing	O
insulin	B:C0021655
resistance	I:C0021655
and	O
thus	O
type	O
2	I:C0011860
diabetes	I:C0011860
,	O
both	O
linked	O
to	O
atherosclerotic	O
cardiovascular	I:C0004153
disease	I:C0004153
.	O

AT	O
inflammation	I:C0030326
is	O
a	O
key	O
factor	O
causing	O
insulin	O
resistance	I:C0021655
and	O
thus	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
,	O
both	O
linked	O
to	O
atherosclerotic	O
cardiovascular	I:C0004153
disease	I:C0004153
.	O

AT	O
inflammation	I:C0030326
is	O
a	O
key	O
factor	O
causing	O
insulin	O
resistance	I:C0021655
and	O
thus	O
type	O
2	I:C0011860
diabetes	I:C0011860
,	O
both	O
linked	O
to	O
atherosclerotic	B:C0004153
cardiovascular	I:C0004153
disease	I:C0004153
.	O

Osteopontin	B:C0069676
(	O
Osteopontin	O
)	O
,	O
a	O
well	O
-	O
known	O
inflammatory	O
cytokine	O
,	O
is	O
involved	O
in	O
obesity	O
-	O
linked	O
complications	O
including	O
AT	O
inflammation	I:C0030326
,	O
insulin	O
resistance	I:C0021655
,	O
atherosclerosis	O
and	O
CVD	O
.	O

Osteopontin	O
(	O
Osteopontin	B:C0069676
)	O
,	O
a	O
well	O
-	O
known	O
inflammatory	O
cytokine	O
,	O
is	O
involved	O
in	O
obesity	O
-	O
linked	O
complications	O
including	O
AT	O
inflammation	I:C0030326
,	O
insulin	O
resistance	I:C0021655
,	O
atherosclerosis	O
and	O
CVD	O
.	O

Osteopontin	O
(	O
Osteopontin	O
)	O
,	O
a	O
well	O
-	O
known	O
inflammatory	O
cytokine	B:C0079189
,	O
is	O
involved	O
in	O
obesity	O
-	O
linked	O
complications	O
including	O
AT	O
inflammation	I:C0030326
,	O
insulin	O
resistance	I:C0021655
,	O
atherosclerosis	O
and	O
CVD	O
.	O

Osteopontin	O
(	O
Osteopontin	O
)	O
,	O
a	O
well	O
-	O
known	O
inflammatory	O
cytokine	O
,	O
is	O
involved	O
in	O
obesity	B:C0028754
-	O
linked	O
complications	O
including	O
AT	O
inflammation	I:C0030326
,	O
insulin	O
resistance	I:C0021655
,	O
atherosclerosis	O
and	O
CVD	O
.	O

Osteopontin	O
(	O
Osteopontin	O
)	O
,	O
a	O
well	O
-	O
known	O
inflammatory	O
cytokine	O
,	O
is	O
involved	O
in	O
obesity	O
-	O
linked	O
complications	B:C0009566
including	O
AT	O
inflammation	I:C0030326
,	O
insulin	O
resistance	I:C0021655
,	O
atherosclerosis	O
and	O
CVD	O
.	O

Osteopontin	O
(	O
Osteopontin	O
)	O
,	O
a	O
well	O
-	O
known	O
inflammatory	O
cytokine	O
,	O
is	O
involved	O
in	O
obesity	O
-	O
linked	O
complications	O
including	O
AT	B:C0030326
inflammation	I:C0030326
,	O
insulin	O
resistance	I:C0021655
,	O
atherosclerosis	O
and	O
CVD	O
.	O

Osteopontin	O
(	O
Osteopontin	O
)	O
,	O
a	O
well	O
-	O
known	O
inflammatory	O
cytokine	O
,	O
is	O
involved	O
in	O
obesity	O
-	O
linked	O
complications	O
including	O
AT	O
inflammation	I:C0030326
,	O
insulin	B:C0021655
resistance	I:C0021655
,	O
atherosclerosis	O
and	O
CVD	O
.	O

Osteopontin	O
(	O
Osteopontin	O
)	O
,	O
a	O
well	O
-	O
known	O
inflammatory	O
cytokine	O
,	O
is	O
involved	O
in	O
obesity	O
-	O
linked	O
complications	O
including	O
AT	O
inflammation	I:C0030326
,	O
insulin	O
resistance	I:C0021655
,	O
atherosclerosis	B:C0004153
and	O
CVD	O
.	O

Osteopontin	O
(	O
Osteopontin	O
)	O
,	O
a	O
well	O
-	O
known	O
inflammatory	O
cytokine	O
,	O
is	O
involved	O
in	O
obesity	O
-	O
linked	O
complications	O
including	O
AT	O
inflammation	I:C0030326
,	O
insulin	O
resistance	I:C0021655
,	O
atherosclerosis	O
and	O
CVD	B:C0007222
.	O

During	O
inflammation	B:C0021368
,	O
Osteopontin	O
is	O
proteolytically	O
cleaved	O
by	O
matrix	O
metalloproteinases	I:C0623362
or	O
thrombin	O
leading	O
to	O
increased	O
Osteopontin	O
activity	O
.	O

During	O
inflammation	O
,	O
Osteopontin	B:C0069676
is	O
proteolytically	O
cleaved	O
by	O
matrix	O
metalloproteinases	I:C0623362
or	O
thrombin	O
leading	O
to	O
increased	O
Osteopontin	O
activity	O
.	O

During	O
inflammation	O
,	O
Osteopontin	O
is	O
proteolytically	B:C0597304
cleaved	O
by	O
matrix	O
metalloproteinases	I:C0623362
or	O
thrombin	O
leading	O
to	O
increased	O
Osteopontin	O
activity	O
.	O

During	O
inflammation	O
,	O
Osteopontin	O
is	O
proteolytically	O
cleaved	B:C0205242
by	O
matrix	O
metalloproteinases	I:C0623362
or	O
thrombin	O
leading	O
to	O
increased	O
Osteopontin	O
activity	O
.	O

During	O
inflammation	O
,	O
Osteopontin	O
is	O
proteolytically	O
cleaved	O
by	O
matrix	B:C0623362
metalloproteinases	I:C0623362
or	O
thrombin	O
leading	O
to	O
increased	O
Osteopontin	O
activity	O
.	O

During	O
inflammation	O
,	O
Osteopontin	O
is	O
proteolytically	O
cleaved	O
by	O
matrix	O
metalloproteinases	I:C0623362
or	O
thrombin	B:C0040018
leading	O
to	O
increased	O
Osteopontin	O
activity	O
.	O

During	O
inflammation	O
,	O
Osteopontin	O
is	O
proteolytically	O
cleaved	O
by	O
matrix	O
metalloproteinases	I:C0623362
or	O
thrombin	O
leading	O
to	O
increased	O
Osteopontin	B:C0069676
activity	O
.	O

Therefore	O
,	O
Osteopontin	B:C0069676
provides	O
a	O
new	O
interesting	O
target	O
for	O
immunological	O
prevention	O
and	O
treatment	O
of	O
obesity	O
-	O
associated	O
diseases	O
.	O

Therefore	O
,	O
Osteopontin	O
provides	O
a	O
new	O
interesting	O
target	O
for	O
immunological	O
prevention	O
and	O
treatment	B:C0087111
of	O
obesity	O
-	O
associated	O
diseases	O
.	O

Therefore	O
,	O
Osteopontin	O
provides	O
a	O
new	O
interesting	O
target	O
for	O
immunological	O
prevention	O
and	O
treatment	O
of	O
obesity	B:C0028754
-	O
associated	O
diseases	O
.	O

Therefore	O
,	O
Osteopontin	O
provides	O
a	O
new	O
interesting	O
target	O
for	O
immunological	O
prevention	O
and	O
treatment	O
of	O
obesity	O
-	O
associated	O
diseases	B:C0012634
.	O

The	O
aim	O
of	O
our	O
study	B:C2603343
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	B:C0220825
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	B:C0030956
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	B:C0042210
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	B:C0021701
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	B:C0005456
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	B:C0069676
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	B:C0021083
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	B:C0040300
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	B:C0021368
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	B:C0021655
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	B:C0004153
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	B:C0012634
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	B:C1366529
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	B:C0026809
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	B:C0012155
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	B:C0028754
model	O
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	B:C0012644
(	O
WT	O
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	B:C1883559
mice	O
)	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
peptide	O
-	O
based	O
vaccines	O
against	O
integrin	O
binding	O
sites	I:C0005456
of	O
Osteopontin	O
and	O
to	O
examine	O
whether	O
these	O
active	O
immunotherapies	O
are	O
functional	O
in	O
reducing	O
metabolic	O
tissue	O
inflammation	O
,	O
insulin	O
resistance	I:C0021655
,	O
and	O
atherosclerosis	O
in	O
a	O
cardio	O
-	I:C0012634
metabolic	I:C0012634
(	O
Ldlr	O
(	O
-	O
/-)	O
mice	O
)	O
and	O
a	O
diet	O
-	O
induced	O
obesity	O
model	O
(	O
WT	O
mice	B:C0026809
)	O
.	O

However	O
,	O
atherosclerosis	B:C0004153
,	O
insulin	O
resistance	I:C0021655
and	O
AT	O
inflammation	I:C0030326
were	O
not	O
diminished	O
after	O
treatment	O
with	O
Osteopontin	O
-	O
derived	O
peptides	O
in	O
murine	O
models	O
.	O

However	O
,	O
atherosclerosis	O
,	O
insulin	B:C0021655
resistance	I:C0021655
and	O
AT	O
inflammation	I:C0030326
were	O
not	O
diminished	O
after	O
treatment	O
with	O
Osteopontin	O
-	O
derived	O
peptides	O
in	O
murine	O
models	O
.	O

However	O
,	O
atherosclerosis	O
,	O
insulin	O
resistance	I:C0021655
and	O
AT	B:C0030326
inflammation	I:C0030326
were	O
not	O
diminished	O
after	O
treatment	O
with	O
Osteopontin	O
-	O
derived	O
peptides	O
in	O
murine	O
models	O
.	O

However	O
,	O
atherosclerosis	O
,	O
insulin	O
resistance	I:C0021655
and	O
AT	O
inflammation	I:C0030326
were	O
not	O
diminished	O
after	O
treatment	B:C0087111
with	O
Osteopontin	O
-	O
derived	O
peptides	O
in	O
murine	O
models	O
.	O

However	O
,	O
atherosclerosis	O
,	O
insulin	O
resistance	I:C0021655
and	O
AT	O
inflammation	I:C0030326
were	O
not	O
diminished	O
after	O
treatment	O
with	O
Osteopontin	B:C0069676
-	O
derived	O
peptides	O
in	O
murine	O
models	O
.	O

However	O
,	O
atherosclerosis	O
,	O
insulin	O
resistance	I:C0021655
and	O
AT	O
inflammation	I:C0030326
were	O
not	O
diminished	O
after	O
treatment	O
with	O
Osteopontin	O
-	O
derived	O
peptides	B:C0030956
in	O
murine	O
models	O
.	O

However	O
,	O
atherosclerosis	O
,	O
insulin	O
resistance	I:C0021655
and	O
AT	O
inflammation	I:C0030326
were	O
not	O
diminished	O
after	O
treatment	O
with	O
Osteopontin	O
-	O
derived	O
peptides	O
in	O
murine	B:C0026809
models	O
.	O

However	O
,	O
atherosclerosis	O
,	O
insulin	O
resistance	I:C0021655
and	O
AT	O
inflammation	I:C0030326
were	O
not	O
diminished	O
after	O
treatment	O
with	O
Osteopontin	O
-	O
derived	O
peptides	O
in	O
murine	O
models	B:C0012644
.	O

Lack	O
of	O
efficacy	O
was	O
based	O
on	O
a	O
failure	O
to	O
induce	O
antibodies	B:C0003241
capable	O
to	O
bind	O
epitopes	O
in	O
the	O
context	O
of	O
functional	O
Osteopontin	O
protein	O
.	O

Lack	O
of	O
efficacy	O
was	O
based	O
on	O
a	O
failure	O
to	O
induce	O
antibodies	O
capable	O
to	O
bind	O
epitopes	B:C0003316
in	O
the	O
context	O
of	O
functional	O
Osteopontin	O
protein	O
.	O

Lack	O
of	O
efficacy	O
was	O
based	O
on	O
a	O
failure	O
to	O
induce	O
antibodies	O
capable	O
to	O
bind	O
epitopes	O
in	O
the	O
context	O
of	O
functional	O
Osteopontin	B:C0069676
protein	O
.	O

Lack	O
of	O
efficacy	O
was	O
based	O
on	O
a	O
failure	O
to	O
induce	O
antibodies	O
capable	O
to	O
bind	O
epitopes	O
in	O
the	O
context	O
of	O
functional	O
Osteopontin	O
protein	B:C0033684
.	O

In	O
conclusion	O
,	O
our	O
data	O
point	O
to	O
unexpected	O
challenges	O
in	O
the	O
immunotherapeutic	B:C0021083
targeting	O
of	O
adhesive	O
motives	O
,	O
such	O
as	O
RGD	O
containing	I:C0052350
sequences	I:C0052350
,	O
on	O
endogenous	O
proteins	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
point	O
to	O
unexpected	O
challenges	O
in	O
the	O
immunotherapeutic	O
targeting	O
of	O
adhesive	O
motives	O
,	O
such	O
as	O
RGD	B:C0052350
containing	I:C0052350
sequences	I:C0052350
,	O
on	O
endogenous	O
proteins	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
point	O
to	O
unexpected	O
challenges	O
in	O
the	O
immunotherapeutic	O
targeting	O
of	O
adhesive	O
motives	O
,	O
such	O
as	O
RGD	O
containing	I:C0052350
sequences	I:C0052350
,	O
on	O
endogenous	O
proteins	B:C0033684
.	O

